Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Director Sells $49,735.59 in Stock
Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) Director Mark Douglas Smith sold 417 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $119.27, for a total value of $49,735.59. Following the completion of the sale, the director now directly owns 6,888 shares of the company’s stock, valued at approximately $821,531.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Jazz Pharmaceuticals Stock Up 0.1 %
NASDAQ JAZZ traded up $0.14 on Wednesday, hitting $121.63. 393,963 shares of the stock traded hands, compared to its average volume of 563,928. The stock has a 50-day moving average of $126.10 and a 200 day moving average of $129.54. Jazz Pharmaceuticals plc has a twelve month low of $111.25 and a twelve month high of $160.96. The company has a market capitalization of $7.66 billion, a P/E ratio of 138.22, a price-to-earnings-growth ratio of 0.96 and a beta of 0.67. The company has a current ratio of 2.06, a quick ratio of 1.67 and a debt-to-equity ratio of 1.46.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported $4.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.21 by $0.01. Jazz Pharmaceuticals had a return on equity of 22.23% and a net margin of 2.11%. The firm had revenue of $972.14 million for the quarter, compared to analysts’ expectations of $969.47 million. As a group, analysts expect that Jazz Pharmaceuticals plc will post 15.41 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on JAZZ. Truist Financial reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday. Needham & Company LLC reissued a “buy” rating and issued a $225.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, November 29th. HC Wainwright reissued a “buy” rating and issued a $204.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, August 11th. Bank of America increased their price target on Jazz Pharmaceuticals from $204.00 to $217.00 and gave the company a “buy” rating in a report on Thursday, August 10th. Finally, Raymond James initiated coverage on Jazz Pharmaceuticals in a report on Thursday, September 28th. They issued a “market perform” rating for the company. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $195.50.
Read Our Latest Report on Jazz Pharmaceuticals
Institutional Trading of Jazz Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of JAZZ. BlackRock Inc. raised its position in shares of Jazz Pharmaceuticals by 3.3% during the 2nd quarter. BlackRock Inc. now owns 6,879,285 shares of the specialty pharmaceutical company’s stock worth $852,825,000 after purchasing an additional 222,801 shares during the period. Vanguard Group Inc. raised its position in shares of Jazz Pharmaceuticals by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 5,888,766 shares of the specialty pharmaceutical company’s stock worth $784,914,000 after purchasing an additional 131,570 shares during the period. Wellington Management Group LLP raised its position in shares of Jazz Pharmaceuticals by 7.5% during the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock worth $408,654,000 after purchasing an additional 184,124 shares during the period. State Street Corp raised its position in shares of Jazz Pharmaceuticals by 1.8% during the 2nd quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock worth $294,106,000 after purchasing an additional 42,703 shares during the period. Finally, LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 2.4% during the 3rd quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock worth $307,055,000 after purchasing an additional 55,630 shares during the period. Institutional investors and hedge funds own 88.15% of the company’s stock.
Jazz Pharmaceuticals Company Profile (Get Free Report)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Jazz Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Jazz Pharmaceuticals wasn’t on the list.
While Jazz Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Original: MarketBeat News Feed: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Director Sells $49,735.59 in Stock